在S1P受体调节剂中,埃特拉西莫德具有独特的药理特性
Ibragim Gaidarov1, H Kiyomi Komori2, Dariusz T Stepniak2
1Beacon Discovery, San Diego, CA, USA.
作为选择性基-1-酸盐 (S1P) 受体调节剂的伊特拉西莫德,与其他S1P调节剂相比,其G蛋白信号传递效率较低,这可能有助于其在性结肠炎治疗中的有利利益风险概况.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 素1-酸盐 (S1P) 受体调节是免疫和心血管系统的关键.
- 选择性S1P受体调节剂 (S1PRMs),如埃特拉西莫德,可为免疫媒介疾病提供向治疗.
- 了解S1PRM差异信号传输对于优化疗效和安全至关重要.
研究的目的:
- 为了比较S1P1-5受体选择性和etrasimod与市场上销售的S1PRMs的下游信号.
- 调查埃特拉西莫德信号特征对心脏功能的影响.
主要方法:
- 在S1P1-5受体之间直接比较埃特拉西莫德,芬戈利莫德,奥萨尼莫德和西波尼莫德.
- 试验包括异质表达系统和人静脉内皮细胞.
- 描述β-arrestin招募,G蛋白激活 (GTPγS结合,cAMP抑制) 和S1P内部化.
主要成果:
- 埃特拉西莫德在β-arrestin招募和S1P1内部化方面表现出与其他S1PRMs相似的功效.
- 与其他测试的S1PRMs相比,Etrasimod在S1P1介导的G蛋白激活中表现出明显较低的强度.
- 这种较低的G蛋白信号传递效能与心脏G蛋白结合内向整顿通道的激活减少相关.
结论:
- 埃特拉西莫德的独特药理特征,以减少G蛋白信号传递为特征,可能是其在性结肠炎中观察到的益处风险概况的基础.
- 不同信号可能有助于提高免疫媒介炎症疾病治疗的安全性和有效性.
更多相关视频
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
10:26Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
Published on: August 18, 2014
相关概念视频
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Dose-Response Relationship: Potency and Efficacy
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Antipsychotic Drugs: Typical and Atypical Agents
